Drugs in Dev.
Infections and Infectious Diseases
IND Enabling
Belgium 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : XVR011
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : VIB
Deal Size : $50.0 million
Deal Type : Series A Financing
ExeVir Announces Close of US$50 million / EUR42 million Series A Financing
Details : Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
March 16, 2021
Lead Product(s) : XVR011
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : VIB
Deal Size : $50.0 million
Deal Type : Series A Financing
